Abstract |
There is evidence to suggest that a dysregulation of endocannabinoid signaling may contribute to the etiology and pathophysiology of migraine. Thus, patients suffering from chronic migraine or medication overuse headache showed alterations in the activity of the arachidonoylethanolamide (AEA) degrading enzyme fatty acid amide hydrolase (FAAH) and a specific AEA membrane transporter, alongside with changes in AEA levels. The precise role of different endocannabinoid system components is, however, not clear. We have therefore investigated mice with a genetic deletion of the two main cannabinoid receptors CB1 and CB2, or the main endocannabinoid degrading enzymes, FAAH and monoacylglycerol lipase (MAGL), which degrades 2-arachidonoylglycerol (2-AG), in a nitroglycerine-induced animal model of migraine. We found that nitroglycerin-induced mechanical allodynia and neuronal activation of the trigeminal nucleus were completely abolished in FAAH-deficient mice. To validate these results, we used two structurally different FAAH inhibitors, URB597 and PF3945. Both inhibitors also dose-dependently blocked nitroglycerin-induced hyperalgesia and the activation of trigeminal neurons. The effects of the genetic deletion of pharmacological blockade of FAAH are mediated by CB1 receptors, because they were completely disrupted with the CB1 antagonist rimonabant. These results identify FAAH as a target for migraine pharmacotherapy.
|
Authors | Chihiro Nozaki, Astrid Markert, Andreas Zimmer |
Journal | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
(Eur Neuropsychopharmacol)
Vol. 25
Issue 8
Pg. 1388-96
(Aug 2015)
ISSN: 1873-7862 [Electronic] Netherlands |
PMID | 25910421
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved. |
Chemical References |
- Analgesics
- Arachidonic Acids
- Benzamides
- CNR1 protein, mouse
- Cannabinoid Receptor Antagonists
- Carbamates
- Cnr2 protein, mouse
- Endocannabinoids
- Enzyme Inhibitors
- Piperidines
- Polyunsaturated Alkamides
- Pyrazoles
- Receptor, Cannabinoid, CB1
- Receptor, Cannabinoid, CB2
- cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
- Monoacylglycerol Lipases
- Amidohydrolases
- fatty-acid amide hydrolase
- Nitroglycerin
- Rimonabant
- anandamide
|
Topics |
- Amidohydrolases
(antagonists & inhibitors, genetics, metabolism)
- Analgesics
(pharmacology)
- Animals
- Arachidonic Acids
- Benzamides
(pharmacology)
- Cannabinoid Receptor Antagonists
(pharmacology)
- Carbamates
(pharmacology)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Endocannabinoids
- Enzyme Inhibitors
(pharmacology)
- Hyperalgesia
(drug therapy, metabolism)
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Migraine Disorders
(drug therapy, physiopathology)
- Monoacylglycerol Lipases
(genetics, metabolism)
- Nitroglycerin
- Pain Measurement
- Piperidines
(pharmacology)
- Polyunsaturated Alkamides
- Pyrazoles
(pharmacology)
- Receptor, Cannabinoid, CB1
(genetics, metabolism)
- Receptor, Cannabinoid, CB2
(genetics, metabolism)
- Rimonabant
- Touch
- Trigeminal Nuclei
(drug effects, physiopathology)
|